Pharmafile Logo

Valeant

- PMLiVE

Novo Nordisk invests £115m in Oxford diabetes unit

But Danish pharma company admitted Brexit had made it a harder decision

- PMLiVE

NICE U-turn on Imbruvica sees the leukaemia therapy backed for NHS use

Institute reverses its initial verdict on Janssen's oncology treatment

- PMLiVE

Takeda UK & Ireland appoints market access director

Peter Wheatley Price brings experience from GSK, Janssen and Boehringer Ingelheim

Actelion HQ Switzerland

J&J agrees $30bn deal to acquire Actelion

Swiss biotech to retain control of early-stage pipeline as J&J takes minority stake in R&D spin-out

- PMLiVE

J&J pondering future of diabetes device assets

Three diabetes care subsidiaries under review as firm forecasts measured 2017 sales

UK flag

Life sciences to play key role in UK’s post-Brexit strategy

Prime minister unveils plans to boost jobs, growth and commercialise country’s science base

- PMLiVE

A rare talent

Shire’s Sebastian Stachowiak on dealing with change and working for a fit-for-purpose orphan drug environment

UK flag

May says UK’s science base is a “negotiating priority” for Brexit

Stokes confidence in UK pharma as science and innovation featured among 12 key priorities

Market access in Europe: balancing access and affordability

European governments continue to pursue national agendas for market access, while also exploring opportunities to work together to achieve lower prices for new drugs

- PMLiVE

Brexit and Trump

The resulting cognitive dissonance from these events is making a lot of people feel very uncomfortable, but has the world really changed?

- PMLiVE

Brexit – a tough pill to swallow

What will be expected of the UK when the post-Brexit environment takes shape?

Shire Basingstoke

Shire pays record $350m to settle US kickback allegations

Charges centred around diabetic foot ulcer treatment Dermagraft, which it sold in 2014

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links